Results 31 to 40 of about 28,652 (194)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk

Frontiers in Cardiovascular Medicine, 2022
ObjectiveTo compare the clinical benefits of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation (NVAF) with high bleeding risk.MethodsA retrospective study was conducted on patients with high bleeding risk NVAF who were ...
Peng-Hui Liu, Ze-Hua Liu, Ming-Hui Niu, Ping Chen, Yuan-Bin Shi, Fei He, Rong Guo   +6 more
doaj   +1 more source

Rivaroxaban in high-risk patients [PDF]

Vnitřní lékařství, 2017
Blockade of factor Xa becomes a routine part of clinical practice instead of vitamin K blockade with warfarin, providing a more beneficial and safer effect. The main indications are prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism.
Jindřich Špinar, Lenka Špinarová
openaire   +2 more sources

The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

Applied Sciences, 2021
Interindividual variabilities between patients taking the anticoagulant rivaroxaban are a result of hepatic metabolism by CYP 450 enzymes. The objective of this study was to evaluate the impact of rivaroxaban on CYP4F2 and transcription factors’ activity
Ieva Ciapiene, Vacis Tatarunas, Agne Giedraitiene, Vaidotas Zvikas, Valdas Jakstas, Audrone Veikutiene, Ugne Meskauskaite, Ugne Venckyte, Audrius Pukalskas, Vaiva Lesauskaite   +9 more
doaj   +1 more source

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations

Pharmaceutics, 2023
Apixaban and rivaroxaban have first-line use for many patients needing anticoagulation for venous thromboembolism (VTE). The pharmacokinetics of these drugs in non-obese subjects have been extensively studied, and, while changes in pharmacokinetics have ...
Cyril Leven, Pauline Ménard, Isabelle Gouin-Thibault, Alice Ballerie, Karine Lacut, Edouard Ollier, Jérémie Théreaux   +6 more
doaj   +1 more source

Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants

Clinical Medicine Insights: Case Reports, 2015
Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an accidental overdose in a patient with pulmonary thromboembolism, when the patient ...
Dimitar Sajkov, Alexander Gallus
doaj   +1 more source

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Pharmaceutics
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects.
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhichun Gu, Qianzhou Lv, Xiaoye Li   +9 more
doaj   +1 more source

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

TH Open, 2017
Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer.
Walter Ageno, Lorenzo G. Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Alexander G. G. Turpie   +8 more
doaj   +1 more source

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits

Open Life Sciences, 2022
The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or ...
Yin Lu, Qi Yuan, Ge Zhiru, Li Jiajin
doaj   +1 more source

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Frontiers in Pharmacology, 2022
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao, Xuening Li, Yanwei Chen, Jie Du, Xiaodong Chen, Dalong Wang, Liyan Wang, Shan Zhao, Changyuan Wang, Changyuan Wang, Qiang Meng, Qiang Meng, Huijun Sun, Huijun Sun, Kexin Liu, Kexin Liu, Jingjing Wu, Jingjing Wu   +17 more
doaj   +1 more source

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia

ClinicoEconomics and Outcomes Research, 2021
Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi ...
Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, Ambaye AS   +5 more
doaj